Literature DB >> 1911148

Renal transplantation in patients with classical haemolytic-uraemic syndrome.

C E Bassani1, J Ferraris, C A Gianantonio, S Ruiz, J Ramirez.   

Abstract

Eighteen records from children with renal transplants (RT) and classical haemolytic-uraemic syndrome (HUS) were reviewed. The mean oliguric period was 17.9 +/- 7.5 days; the interval between acute phase and end-stage renal disease (ESRD) was 9.3 +/- 5.2 years. HUS was the most frequent cause of renal transplantation (23.4%). There were no significant differences between patients with HUS and controls (children with RT but without HUS), regarding renal function, frequency of rejections, renal survival (HUS 65%, controls 57%) or patient survival (94.4% and 96.6%, respectively) after 9 years. None had clinical or histopathological evidence of HUS recurrence in the allograft. Of all children with living-related donors (LRD), renal survival after 3 years was longer for those who received cyclosporin A (CSA) (HUS and controls 86%) than for those who did not receive it (HUS 50%, controls 53%). Classical HUS is a frequent cause of ESRD in Argentina. The duration of the acute oliguric period is a good predictor of the likelihood of progression to chronicity. In the classical form of HUS there is no recurrence in the allograft. CSA and LRD can be used without risk in renal transplantation of children with classical HUS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911148     DOI: 10.1007/bf00856651

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  16 in total

1.  THE HEMOLYTIC-UREMIC SYNDROME.

Authors:  C GIANANTONIO; M VITACCO; F MENDILAHARZU; A RUTTY; J MENDILAHARZU
Journal:  J Pediatr       Date:  1964-04       Impact factor: 4.406

2.  Renal transplantation in 20 children with hemolytic-uremic syndrome.

Authors:  F J Eijgenraam; R A Donckerwolcke; L A Monnens; W Proesmans; E D Wolff; B van Damme
Journal:  Clin Nephrol       Date:  1990-02       Impact factor: 0.975

3.  Haemolytic uraemic syndrome associated with faecal cytotoxin and verotoxin neutralizing antibodies.

Authors:  A A Novillo; L E Voyer; R Cravioto; M C Freire; G Castaño; R Wainstein; N Binztein
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

4.  The hemolytic-uremic syndrome.

Authors:  C A Gianantonio; M Vitacco; F Mendilaharzu; G E Gallo; E T Sojo
Journal:  Nephron       Date:  1973       Impact factor: 2.847

5.  Recurrence of hemolytic uremic syndrome in renal transplant recipients.

Authors:  D Hebert; R K Sibley; S M Mauer
Journal:  Kidney Int Suppl       Date:  1986-07       Impact factor: 10.545

6.  Cyclosporin-induced haemolytic uraemic syndrome in liver allograft recipient.

Authors:  R S Bonser; D Adu; I Franklin; P McMaster
Journal:  Lancet       Date:  1984-12-08       Impact factor: 79.321

Review 7.  HUS and TTP: variable expression of a single entity.

Authors:  G Remuzzi
Journal:  Kidney Int       Date:  1987-08       Impact factor: 10.612

8.  Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome.

Authors:  S Ashkenazi; T G Cleary; E Lopez; L K Pickering
Journal:  J Pediatr       Date:  1988-12       Impact factor: 4.406

9.  Renal homotransplantation in infants and children with the hemolytic-uremic syndrome.

Authors:  G J Cerilli; C Nelsen; L Dorfmann
Journal:  Surgery       Date:  1972-01       Impact factor: 3.982

10.  Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia.

Authors:  R L Powles; G R Morgenstern; H E Kay; T J McElwain; H M Clink; P J Dady; A Barrett; B Jameson; M H Depledge; J G Watson; J Sloane; M Leigh; H Lumley; D Hedley; S D Lawler; J Filshie; B Robinson
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

View more
  8 in total

Review 1.  Glomerular disease of transplanted kidneys.

Authors:  U Frei
Journal:  Clin Investig       Date:  1993-10

2.  Renal allograft survival according to primary diagnosis: a report of the North American Pediatric Renal Transplant Cooperative Study.

Authors:  C E Kashtan; P T McEnery; A Tejani; D M Stablein
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

Review 3.  Heterogeneity of atypical haemolytic uraemic syndromes.

Authors:  T J Neuhaus; S Calonder; E P Leumann
Journal:  Arch Dis Child       Date:  1997-06       Impact factor: 3.791

Review 4.  Non-immunological risk factors in paediatric renal transplantation.

Authors:  M F Gagnadoux; P Niaudet; M Broyer
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

5.  Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome.

Authors:  María Gracia Caletti; Horacio Lejarraga; Diana Kelmansky; Mabel Missoni
Journal:  Pediatr Nephrol       Date:  2004-06-18       Impact factor: 3.714

6.  Cerebral infarct with recurrence of hemolytic-uremic syndrome in a child following renal transplantation.

Authors:  M Mochon; B A Kaiser; J P deChadarevian; M S Polinsky; H J Baluarte
Journal:  Pediatr Nephrol       Date:  1992-11       Impact factor: 3.714

7.  Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential.

Authors:  Frances Dowen; Katrina Wood; Alison L Brown; Jennifer Palfrey; David Kavanagh; Vicky Brocklebank
Journal:  Clin Kidney J       Date:  2017-05-08

Review 8.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review.

Authors:  Adrien Joseph; Aurélie Cointe; Patricia Mariani Kurkdjian; Cédric Rafat; Alexandre Hertig
Journal:  Toxins (Basel)       Date:  2020-01-21       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.